Sayniska JBS ee fadhigiisu yahay Pennsylvania ayaa sheegay maanta inay ka heshay $ 3 milyan Abaalmarinta Buundada Cilmi-baarista Hal-abuurka Ganacsiga Yaryar ee IIB ee Machadka Qaranka ee Kansarka. Shirkaddu waxay soo saartay alaabtii ugu horreysay ee dheecaanka-qaadista, taasoo ah baaritaanka DNA-da kaadida ee kansarka unugyada beerka hore (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of kansarka beerka. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating buro DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS waxay sheegtay inay la kaashatay James Hamilton oo ka tirsan Xarunta Caafimaadka ee Jaamacadda Johns Hopkins iyo Hie-Won Hann oo ka tirsan Isbitaalka Jaamacadda Thomas si loo horumariyo horumarinta baaritaanka kaadida kansarka beerka.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
